Proximal Ventures Closes $27.5M Debut Fund for AI Life Sciences

Proximal Ventures announced on November 10, 2026 that it had closed its debut fund at $27.5 million, exceeding its $25 million target to back pre-seed and seed companies building AI-native infrastructure across the life-sciences value chain.

The oversubscription itself signals demand. A first-time fund from a solo founding general partner, raised in 2026 and closed above target, landed in a year when investors have pushed capital toward AI applications in regulated industries. The firm's bet is specific: the value in AI for pharmaceuticals does not stop at molecule discovery, and the hundreds of billions of dollars spent annually on pharmaceutical services are ripe for reconstruction.

Who is behind the fund?

Proximal Ventures is an independent venture firm based in San Francisco, founded by Sahir Raoof in 2026. Its strategic partners in Fund I include Domino Lane, SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments and PagsGroup. Individual investors include Dimension co-founders Nan Li and Zavain Dar.

The partner list carries weight for a debut vehicle. SignalFire, where Raoof previously led techbio and pharmatech investing, is also a strategic partner in the new fund. Kleiner Perkins brings decades of life-sciences investing history. Bertelsmann Healthcare Investments extends the fund's reach into a global corporate investing base.

Raoof's own record spans more than a decade of building and investing in companies that serve life sciences. He was Iterative Health's first commercial hire and vice president of business development. He built biopharma research partnerships at Flatiron Health. He covered biotechnology and outsourced pharmaceutical services at J.P. Morgan. Before launching Proximal, he led techbio and pharmatech investing at SignalFire.

That trajectory — operator, banker, investor — frames the fund's thesis. Raoof has worked on the commercial side of life-sciences companies, not only on the research side, and Fund I reflects that orientation.

What does the fund actually invest in?

The firm's published criteria set initial checks at $500,000 to $1.5 million. The target companies are pre-seed and seed stage, building AI-native infrastructure for the life-sciences value chain.

The mandate is deliberately broader than drug discovery. Proximal is looking for systems that:

• improve discovery and clinical-trial speed
• reinforce manufacturing resilience
• increase supply-chain visibility
• sharpen commercial execution

Those criteria span clinical development, manufacturing and commercialization. The firm is not limiting itself to the search for new molecules. Instead, it treats the operational layers of pharmaceutical development — the stages between an AI-enabled discovery and a medicine reaching patients — as the investable surface.

Proximal says it wants to improve the speed, cost and reliability of getting better medicines to patients. Its method: build on existing discovery advances and transform the hundreds of billions of dollars spent annually on pharmaceutical services.

Raoof said: "Some of the greatest opportunities lie in areas that have historically attracted less venture investment, and we see tremendous potential to build important companies throughout the value chain."

The quote names the gap the fund exists to fill. Manufacturing resilience, supply-chain visibility and commercial execution have drawn less venture capital than discovery and clinical AI. Proximal is positioning itself in that underfunded middle.

Why the post-discovery stages matter

Jim Lim, managing partner at Domino Lane, framed the thesis from the strategic partner's side. The clinical, manufacturing, regulatory and commercial work that follows discovery plays a major role in whether a drug succeeds, he said, and few investors understand those functions collectively.

That perspective shapes how Fund I deploys. Proximal is pairing capital with pharmaceutical expertise for the stages between an AI-enabled discovery and a medicine reaching patients. The advisory and customer network is central to that strategy, not an accessory to it.

The distinction matters for founders. A company selling AI infrastructure to pharmaceutical manufacturers or commercial teams faces buyers that discovery-focused investors rarely know. Proximal's network is built to open those doors.

How early does Proximal engage?

Earlier than incorporation, in some cases. Proximal begins working with founders at the idea stage, testing concepts and developing go-to-market plans. It also introduces founders to pharmaceutical executives, design partners and customers — with some of this work taking place before a company is formally incorporated.

That pre-company support is unusual for check sizes of $500,000 to $1.5 million. It reflects the firm's argument that AI-native life-sciences infrastructure companies fail most often on distribution and domain fit, not on technology. Working with founders before incorporation lets Proximal shape both.

Who advises the fund?

The advisory network includes Amy Abernethy, co-founder of Highlander Health and former principal deputy commissioner of the U.S. Food and Drug Administration, and Kim Branson, GSK's chief AI officer.

Abernethy's presence connects the fund to regulatory experience at the highest level of U.S. drug oversight. Branson's connects it to the AI leadership of one of the world's largest pharmaceutical companies. For pre-seed founders building infrastructure for clinical development or manufacturing, both affiliations map directly onto the buyers and regulators they will face.

Rohit Gupta, co-founder and CEO of Chronicle Bio, described the practical value of the relationship. Proximal contributes industry relationships, knowledge of its data ecosystem and advice through its network, he said, as Chronicle Bio works to eliminate the burden of complex chronic disease.

What has the fund done so far?

Proximal says it has earned allocations in competitive rounds alongside multi-stage firms since it began deploying Fund I. With the fund now closed, the firm is actively investing in new life-sciences companies.

Winning allocations in competitive rounds is the standard credibility test for a pre-seed fund, and Proximal reports passing it before announcing the close. The firm did not disclose the number of investments made or the names of portfolio companies beyond its work with founders such as Gupta.

The competitive positioning is clear. Multi-stage firms have moved earlier into AI life sciences, and pre-seed founders can now choose between sector specialists and large platforms. Proximal's differentiator is the pairing of small checks with a pharmaceutical operating network — Abernethy on regulation, Branson on AI inside a top-20 pharma, and a partner roster that includes SignalFire and Kleiner Perkins.

The bet, reduced to its core: discovery AI has attracted the capital and the headlines, while the clinical, manufacturing and commercial systems that determine whether a drug succeeds have not. Fund I's $27.5 million is aimed at that gap. If Raoof's thesis holds, the next cohort of durable AI life-sciences companies will be built in the stages the venture industry has historically passed over — and Proximal will have bought in before incorporation.